Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens
- 28 April 2022
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 60 (7) , 1116-1123
Abstract
Objectives: Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19) presents occasionally with an aberrant autoinflammatory response, including the presence of elevated circulating autoantibodies in some individuals. Whether the development of autoantibodies against self-antigens affects COVID-19 outcomes remains unclear. To better understand the prognostic role of autoantibodies in COVID-19, we quantified autoantibodies against 23 markers that are used for diagnosis of autoimmune disease. To this end, we used serum samples from patients with severe [intensive care unit (ICU)] and moderate (ward) COVID-19, across two to six consecutive time points, and compared autoantibody levels to uninfected healthy and ICU controls. Methods: Acute and post-acute serum (from 1 to 26 ICU days) was collected from 18 ICU COVID-19-positive patients at three to six time points; 18 ICU COVID-19-negative patients (sampled on ICU day 1 and 3); 21 ward COVID-19-positive patients (sampled on hospital day 1 and 3); and from 59 healthy uninfected controls deriving from two cohorts. Levels of IgG autoantibodies against 23 autoantigens, commonly used for autoimmune disease diagnosis, were measured in serum samples using MSD® U-PLEX electrochemiluminescence technology (MSD division Meso Scale Discovery®), and results were compared between groups. Results: There were no significant elevations of autoantibodies for any of the markers tested in patients with severe COVID-19. Conclusions: Sample collections at longer time points should be considered in future studies, for assessing the possible development of autoantibody responses following infection with SARS-CoV-2.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health (U24AI118660)
- University of Toronto (Unassigned)
- Canada First Research Excellence Fund (Unassigned)
- National Institute of Allergy and Infectious Diseases (Unassigned)
This publication has 23 references indexed in Scilit:
- A living WHO guideline on drugs for covid-19 (2020-2023)BMJ, 2020
- An inflammatory cytokine signature predicts COVID-19 severity and survivalNature Medicine, 2020
- Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolismThrombosis Research, 2020
- Drug treatments for covid-19: living systematic review and network meta-analysisBMJ, 2020
- Interpreting Diagnostic Tests for SARS-CoV-2JAMA, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- The trinity of COVID-19: immunity, inflammation and interventionNature Reviews Immunology, 2020
- Quantitative Mass Spectrometric Analysis of Autoantibodies as a Paradigm Shift in Autoimmune SerologyFrontiers in Immunology, 2019
- A proteome-wide immuno-mass spectrometric identification of serum autoantibodiesClinical Proteomics, 2019
- Diagnostic testing and interpretation of tests for autoimmunityJournal of Allergy and Clinical Immunology, 2010